Kiniksa Pharmaceuticals International, plc (KNSA) Q1 2026 Earnings Call Transcript
Kiniksa Pharmaceuticals International, plc held its Q1 2026 earnings call on April 28, 2026, reviewing financial results and progress across its drug development and commercialization programs. The company provided updates on ARCALYST's commercial performance and the Phase II/III trial of KPL-387 for recurrent pericarditis. Leadership discussed operational execution and financials, with CFO Mark Ragosa presenting the quarter's results. CEO Sanj Patel concluded with strategic outlook and opened the call to analyst questions.
- ▪Kiniksa reported its first quarter 2026 financial results during the April 28, 2026 earnings call.
- ▪Ross Moat provided an update on the commercial execution of ARCALYST.
- ▪Dr. John Paolini reviewed the ongoing Phase II/III clinical trial of KPL-387 in recurrent pericarditis.
- ▪Mark Ragosa presented Kiniksa's Q1 2026 financial performance.
- ▪CEO Sanj Patel offered closing remarks and participated in the Q&A session alongside Chief Strategy Officer Eben Tessari.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4895361-kiniksa-pharmaceuticals-international-plc-knsa-q1-2026-earnings-call-transcript"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
